Prognosis for ER-Negative, Weakly PR-Positive, HER2-Equivocal Breast Cancer
This tumor profile carries a poor prognosis, comparable to triple-negative breast cancer, and requires immediate HER2 reflex testing to determine definitive treatment strategy.
Critical First Step: Resolve HER2 Status
Your HER2-equivocal result must be resolved immediately through reflex testing with the alternative assay (if initial test was IHC, perform ISH; if initial was ISH, perform IHC) 1, 2. This is non-negotiable because HER2 status fundamentally alters both prognosis and treatment options. Do not delay treatment decisions while HER2 status remains uncertain 1.
Prognostic Assessment
If HER2 Ultimately Negative:
This represents a high-risk subtype with survival outcomes similar to or worse than triple-negative breast cancer 3, 4, 5, 6. The evidence is clear:
- ER-/PR+ tumors behave like triple-negative disease, not like hormone receptor-positive cancers 5, 6
- Median overall survival in metastatic setting: approximately 12-16 months, comparable to triple-negative breast cancer 5, 6
- These tumors preferentially metastasize to visceral organs rather than bone 5
- Weak PR positivity (which you describe) offers minimal to no prognostic benefit 4, 7
Critical caveat: High PR expression (>20% of cells) in ER-negative tumors is actually an adverse prognostic factor (HR 5.0 for death) 4. However, your "weakly positive" designation suggests low-level expression, which places this tumor in the worst prognostic category.
If HER2 Ultimately Positive:
The prognosis improves substantially with access to HER2-targeted therapies 8, 9. HER2-positive disease, even when ER-negative, responds well to trastuzumab-based combinations with significant survival benefits 8, 9.
Biological Reality vs. Technical Artifact
The ER-/PR+ phenotype is real but uncommon (1-4% of breast cancers) 7, 10. However, up to 35% of initially reported ER-/PR+ cases are reclassified upon retesting with multiple antibody clones 4. Key points:
- Approximately 35% become ER-positive with alternative antibody testing 4
- Another 9% become completely hormone receptor-negative 4
- Only about 56% retain the ER-/PR+ designation after comprehensive re-evaluation 4
Recommendation: Consider retesting ER status with multiple validated antibody clones (SP1, 1D5, EP1) if tissue is available 4. This could reclassify the tumor and alter treatment strategy.
Treatment Implications Based on Final HER2 Status
If HER2-Negative Confirmed:
- Treat as triple-negative breast cancer with chemotherapy as primary systemic therapy 11, 5, 6
- Endocrine therapy alone is insufficient for this subtype 6
- Consider chemotherapy followed by endocrine therapy, which may provide some benefit 12
- Do not rely on endocrine therapy as sole treatment despite PR positivity 5, 6
If HER2-Positive Confirmed:
- Standard HER2-targeted therapy (trastuzumab + pertuzumab + taxane first-line) is indicated 9
- Consider adding endocrine therapy to HER2-targeted regimen given PR positivity, though benefit is uncertain in ER-negative disease 13, 9
If HER2 Remains Equivocal After Reflex Testing:
- May consider HER2-targeted therapy on individualized basis given the poor prognosis of ER-/PR+ disease 1
- Recent data on HER2-low disease (IHC 1+ or 2+/ISH non-amplified) shows benefit from trastuzumab deruxtecan 14
- This patient may qualify for HER2-low directed therapy depending on final IHC score
Additional Prognostic Factors to Assess
Beyond receptor status, evaluate:
- Tumor grade: ER-/PR+ tumors are typically high grade 5, 7
- Nodal involvement: Single most important prognostic factor in this subtype 10
- Visceral vs. bone metastases: This subtype preferentially spreads to viscera 5
- Age: Younger patients (<40) have slightly higher rates of this subtype 15
Bottom Line
This tumor carries a poor prognosis similar to triple-negative breast cancer, with median survival of 12-16 months in the metastatic setting 5, 6. The weak PR positivity provides minimal prognostic benefit and should not be interpreted as indicating hormone-responsive disease 4, 6. Immediate HER2 reflex testing is mandatory to determine if HER2-targeted therapy can improve outcomes 1, 2. If HER2-negative, aggressive chemotherapy-based treatment is required, not endocrine therapy alone 5, 6.